This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamid…

Refractory Solid TumorHepatocellular CarcinomaMalignant Solid Tumor+3 more

~Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT05468359

Phase 1

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (A…

Advanced Solid TumorCutaneous TumorSubcutaneous Tumor+6 more

~Estimated

~$10 – $8,750

Ankyra Therapeutics, IncNCT06171750

Phase 1

A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies

This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in …

Ovarian CancerAdvanced Malignant Solid Tumor

~Estimated

~$10 – $6,250

University of ChicagoNCT07389239

← PreviousPage 2 of 2Next →